Skip to main content
SpringerLink
Log in

Endocrine options for Breast Cancer treatment: Looking beyond Tamoxifen

  • Satellite Symposium I
  • Published:
Breast Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

NSABP:

National Surgical Adjuvant Breast and Bowel Project

BCPT:

Breast Cancer Prevention Trial

CI:

Confidence interval

CMF:

Cyclophosphamide, methotrexate, and 5-fluorouracil

CAF:

Cyclophosphamide, doxorubicin, 5-fluorouracil

ZIPP:

Zoladex in Premenopausal patients

ZEBRA:

Zoladex Early Breast Cancer Research Association

ATAC:

Arimidex, Tamoxifen, Alone or in Combination

LH:

Luteinizing hormone

FSH:

Follicle-stimulating hormone

UFT:

Tegafur

CEA:

Carcinoembryonic antigen

CA:

Cancer antigen

MPA:

Medroxyprogesterone acetate

LH-RH:

Luteinizing hormone releasing-hormone

CRH:

Corticotropin-releasing hormone

ACTH:

Adrenocorticotrophic hormone

Author information

Authors and Affiliations

  1. Department of Internal Medicine, National Cancer Center Hospital, Japan

    Toru Watanabe

  2. Department of Surgery, Kawasaki Medical School, Japan

    Hiroshi Sonoo

Authors
  1. Toru Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Sonoo
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Watanabe, T., Sonoo, H. Endocrine options for Breast Cancer treatment: Looking beyond Tamoxifen. Breast Cancer 7, 345–349 (2000). https://doi.org/10.1007/BF02966403

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02966403

Key words

Search

Navigation